LifeMD’s EBITDA Timelines and GLP-1 Economics Clash in Q2 2026 Earnings Call

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $47.3 million, down approximately 4% YOY and down approximately 6% sequentially
• EPS: $0.16 loss per share
• Gross Margin: 89%, an improvement of approximately 60 basis points sequentially

Guidance:

• Full-year 2026 revenue outlook revised to $205.5 million to $212.5 million.
• Full-year 2026 adjusted EBITDA outlook revised to negative $6 million to break even.
• Q3 2026 revenue expected in range of $48 to $51 million; EBITDA expected in range of negative $1 million to positive $2 million.
• Q4 2026 revenue expected in range of $60 to $64 million; EBITDA expected between $3 million and $6 million.
• Expect return to adjusted EBITDA profitability in Q3 and substantial sequential improvement in Q4.

Business Commentary:

Revenue and Profitability Trends:

• LifeMD reported revenue of $47.3 million for the second quarter, within the guidance range but down approximately 6% sequentially.
• Adjusted EBITDA was a loss of approximately $3.5 million, impacted by elevated customer acquisition costs and a new $39 introductory offer in weight management.
• The company is shifting its customer acquisition model, aiming to reduce reliance on paid media and diversify growth channels, which contributed to the short-term profitability pressure.

Weight Management Segment Dynamics:

• LifeMD's weight management business saw a significant shift with approximately 85% of new patients selecting multi-month packages after the introductory price was lowered to $39.
• This strategic pricing decision, despite reducing upfront cash collection, improved patient attraction and cohort quality, supporting long-term patient relationships and higher lifetime value.

Gross Margin and Operating Cost Management:

• Gross margin expanded to approximately 89%, improving 60 basis points sequentially, driven by lower shipping costs and improved provider efficiency.
• Advertising and marketing expenses declined by approximately $1.8 million sequentially, and G&A expenses dropped by $1.5 million, reflecting the company's efforts to optimize operating costs.

Strategic Shift and Diversification:

• LifeMD is broadening its acquisition model beyond paid media, focusing on pharmaceutical partnerships, insurance, and Medicare to build a more durable business.
• The company is investing in branded therapies, a growing affiliated medical group, and a scalable pharmacy operation to enhance revenue diversity and reduce volatility.

Women's Health Growth:

• The women's health program reported a 134% quarter-over-quarter growth in the patient base, with new patient acquisitions increasing substantially.
• This growth is underpinned by a focus on longitudinal, evidence-based care, aiming to establish it as one of LifeMD's core businesses with strong retention and engagement.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed optimism about strategic progress: 'We are building for the patients who use LifeMD for more of their healthcare over time... The model is working as designed.' They noted strong trends in unit economics, recurring revenue (84% of total), and multiple new growth channels (e.g., Zyestad partnership, women's health). The outlook for 2027 is optimistic, with expectations for significant contributions from new initiatives.

Q&A:

• Question from David Larson (BTIG): Can you talk about peptides and the discussions in Washington? What is the potential revenue opportunity?
  Response: Management sees significant demand potential if FDA permits peptides, but does not have a specific revenue number. They are preparing sterile compounding capabilities and plan a conservative, safety-focused approach.

• Question from David Larson (BTIG): What portion of weight management subscribers are on compounded vs. branded GLP-1? Any fulfillment fees from Lilly or Novo?
  Response: New patients are nearly 95% on branded therapies; branded business has attractive unit economics. Relationships with Lilly and Novo are positive but currently only involve integrations, not economics.

• Question from Sarah James (Cantor Fitzgerald): If new initiatives (Zyosted, Medicare, employer partnerships, pharmacy) reach scale, what is the potential for 2027 EBITDA margin growth vs. ~10% exit in 2026?
  Response: Management is optimistic about 2027, citing strong base business improvement, new product pipeline, and growth from initiatives like Zyosted, though contributions will take time to mature.

• Question from Sarah James (Cantor Fitzgerald): Where do you stand on deep customer relationships across multiple health areas, and where could that go in a couple of years?
  Response: Deeper relationships are already evident in women's health and will expand in weight management. The vision involves cross-care integration, AI-driven longitudinal care, and medication management.

• Question from Steve Deschartes (KeyBank Capital Markets): What is insurance usage among patients currently vs. historically, and what is the expectation for growth?
  Response: Currently, about 10% of new patients use insurance, up from a smaller base previously. Demand is growing, and insurance is seen as an important differentiator for long-term growth.

• Question from Yi Chen (HC Wainwright): Can you provide more color on women's health, including subscribers or revenue?
  Response: Women's health is not yet at $5 million quarterly revenue run rate by Q4, but the target is $3-$5 million. New patient acquisitions are strong (50-100 per day), with excellent unit economics and growth prospects.

Contradiction Point 1

Financial Outlook and EBITDA Contribution Timeline

Timeline for EBITDA contribution from new initiatives appears to have shifted, affecting financial planning and investor expectations.

Sarah James (Cantor Fitzgerald) - Sarah James (Cantor Fitzgerald)

2026Q2: Initial cohorts are expected to become EBITDA-accretive in mid-2027. - Justin Schreiber(CEO)

Considering the 2026 build years in Medicare, employer partnerships, and pharmacy, what is the potential for 2027 EBITDA margin growth from the ~10% exit rate, and which of these initiatives is likely to show a visible impact first? - Sarah James (Cantor Fitzgerald)

20260310-2025 Q4: It is expected to be slightly accretive by Q4 2026 run rate and significantly so in 2027. - Marc Benathen(CFO)

Contradiction Point 2

Financial Outlook and Impact of Strategic Shift to Branded GLP-1

Contradiction on the financial impact of shifting from compounded to branded GLP-1 therapies, affecting unit economics assessment.

David Larson (BTIG) - David Larson (BTIG)

2026Q2: The shift... has a profound positive impact on unit economics, improving both EBITDA and cash collection profiles. - Atul Kastakar(CFO)

What portion of the 108,000 weight management subscribers are on compounded versus branded GLP-1, and can you comment on the economics of branded therapies (Lilly, Novo) and whether fulfillment fees are received? - Ryan Meyers (Lake Street Capital)

2026Q1: The deliberate strategic shift... results in lower revenue per patient (unit economics) for branded drugs. - Atul Kavthekar(CFO)

Contradiction Point 3

Nature of Relationships with Lilly and Novo and Associated Economics

Contradiction on whether economic benefits from partnerships with Lilly and Novo are currently realized, impacting perceived business model stability.

David Larson (BTIG) - David Larson (BTIG)

2026Q2: Currently, relationships with Lilly and Novo are just integrations; no economics or fulfillment fees are received. - Justin Schreiber(CEO)

What portion of the 108,000 weight management subscribers are on compounded versus branded GLP-1, and can you comment on the economics of branded therapies (Lilly, Novo) and whether fulfillment fees are received? - David Larsen (BTIG)

2026Q1: discussions are ongoing and productive, with optimism that the relationships will evolve in the near term... to improve unit economics and patient access. - Justin Schreiber(CEO)

Contradiction Point 4

Subscriber Mix and Economics for Branded GLP-1 Therapies

Contradiction on the scale and economic significance of the branded GLP-1 subscriber base, affecting revenue growth narrative.

David Larson (BTIG) - David Larson (BTIG)

2026Q2: The branded GLP-1 market is now dominant. ~95% of new patients are starting on branded therapies.... Currently, relationships with Lilly and Novo are just integrations; no economics or fulfillment fees are received. - Justin Schreiber(CEO)

What portion of the 108,000 weight management subscribers are on compounded versus branded GLP-1, and how do the economics of branded therapies (e.g., Lilly, Novo) compare to competitors, including whether fulfillment fees are received? - David Larsen (BTIG)

20260310-2025 Q4: Unit economics are encouraging, justifying increased marketing investment. Revenue increase through 2026 will be primarily driven by subscriber count growth in GLP-1 weight management... - Justin Schreiber(CEO) and Marc Benathen(CFO)

Contradiction Point 5

Women's Health Segment Revenue Run Rate Guidance

Guidance for achieving a $3M-$5M quarterly revenue run rate by Q4 2026 appears inconsistent.

Okay, let's see. The user wants me to take the input "Yi Chen (HC Wainwright)" and turn it into a concise earnings-call question. The rules are strict: only one line, no explanations, just the question ending with a question mark if possible. First, I need to figure out what the input represents. "Yi Chen" is a name, probably an analyst or a person from the company. "HC Wainwright" is likely the firm or department they're from. In earnings calls, people often ask questions about financial results, strategies, challenges, or future plans.Since there's no specific question in the input, I need to infer a possible question that would make sense in an earnings call context. Maybe Yi Chen from HC Wainwright is asking about the company's performance. Common questions could be about revenue growth, profit margins, market challenges, or future projections. But the input doesn't provide any specific details. The user's instruction says if the input is too vague, output it as-is. However, maybe there's a standard way to form a question from an analyst's name. For example, "What are your thoughts on the recent financial results?" or "Can you comment on the challenges faced in the quarter?"Alternatively, maybe the user expects a generic question directed to the company's management. Since the input is just a name and a firm, the question should be something that an analyst might ask during an earnings call. So, a possible question could be: "Yi Chen (HC Wainwright) asks about the company's earnings performance and future outlook?"But the rules say to output exactly one line and only the final question. Also, the output must end with a question mark if it's a rewrite. Since the original input isn't a question, but the name of the person, perhaps the correct approach is to form a question that the person would ask. However, without knowing the specific topic, it's hard. The safest way under the rules might be to output the input as-is if it's too vague. But maybe the user expects a standard question like "What are your comments on the earnings report?" So, combining the name with that.Wait, the example in the rules says if the input isn't a question or too vague, output as-is. But here, the input is a name and a firm. It's not a question. So according to the rules, if the input is not a question, output as-is. But maybe the user expects that even if it's not a question, we can form a question from it. The instruction says to rewrite into one concise earnings-call question. So perhaps the correct approach is to create a question that would be asked by Yi Chen from HC Wainwright. For example: "Yi Chen (HC Wainwright) asks about the company's earnings performance and future outlook?"But the rules say the output must be exactly one line, only the question text, ending with a question mark. So maybe the correct question is "What are your comments on the earnings report, Yi Chen (HC Wainwright)?" But that's directing the question to the person, which might not be right. In earnings calls, the question is usually directed to the company. So perhaps "Yi Chen (HC Wainwright) asks about the company's earnings performance and future outlook?" But that's a bit long. Alternatively, "Can you discuss the earnings results and future plans?" with the analyst's name in parentheses. But the rules say to output exactly the question. Maybe the standard format is "Yi Chen (HC Wainwright) asks: [question]?" But the rules don't allow for that structure. The user wants the question itself, not the attribution. Wait, the example input is a name, and the output should be a question. But the input isn't a question. So perhaps the correct output is to form a question that would be asked by Yi Chen. However, without knowing the specific topic, the best we can do is a generic question. So the final answer would be something like "What are your comments on the earnings report?" but with the analyst's name included. However, the rules state that the output must be only the final question text. So maybe "What are your comments on the earnings report?" but that doesn't include the name. The input is the name of the person asking. But the output is supposed to be the question. The user might want the question to include the name. But the rules don't mention including the name. The example in the rules says to output the input as-is if it's not a question. However, the instruction says to rewrite the input into one concise earnings-call question. So perhaps the correct approach is to create a question that would be asked by Yi Chen from HC Wainwright. For example: "Yi Chen (HC Wainwright) asks about the company's earnings performance and future outlook?" But that's a statement - Yi Chen (HC Wainwright)

2026Q2: The business is not yet at a $5M quarterly run rate as previously guided, but should reach a $3M-$5M quarterly revenue run rate by Q4 2026. - Justin Schreiber(CEO)

Can you provide ending subscribers, quarterly revenue, and expectations for the ramp to the end of the year in the women's health segment? - Yi Chen (HC Wainwright)

2026Q2: Revenue Run Rate: The business is expected to reach a quarterly revenue run rate of $3-$5 million by Q4 2026, though this may be a bit aggressive. - Justin Schreiber(CEO)